Genetic medicine specialist Lexeo Therapeutics is the latest biotech to line up an initial public offering (IPO), aiming to raise around $100 million from the transaction.
In the ever-evolving landscape of the biotechnology sector, the ability to attract investors effectively stands as the decisive factor that separates the success of your pioneering research
Sangamo Therapeutics has announced another wave of job losses and a plan to license out two lead clinical programmes as it tries to reinvent itself as a neurology-focused
Biotech investment may be somewhat in the doldrums at the moment, but the sector continues to see a steady stream of deals – particularly in the venture capital category –
International healthcare investment group OrbiMed has raised around $4.3 billion in committed financing for distribution across three new private funds that will be used t
In this latest instalment of the pharmaphorum podcast, web editor Nicole Raleigh speaks with life sciences advisor Randall Hein, CEO of Heinsight LLC, and health sciences marketing expert K